Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI United Kingdom (FTSE) (EWU) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

iShares MSCI United Kingdom (FTSE)Trade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI United Kingdom (FTSE) vs Zimmer Biomet Holdings Inc — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.38 (market cap $3.62B), while Zimmer Biomet Holdings Inc trades at $88.98 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 4.7× iShares MSCI United Kingdom (FTSE)'s market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while iShares MSCI United Kingdom (FTSE) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 46 Days and Zimmer Biomet Holdings Inc for 89 Days on average.

EWUZBH
Market Cap
$3.62B$16.95B
Volume
923,8962,505,240
Sector
Broad Market / FactorHealth
52-Week High
$49.39$103.98
52-Week Low
$41.34$79.58
Typical Hold Time
46 Days89 Days
Enterprise Value
—$24.02B
Dividend Yield
—1.08%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI United Kingdom (FTSE)

EWU, the iShares MSCI United Kingdom ETF, is trading at $45.93, down 0.95% amid broader market pressures. Technical indicators show a bearish trend with moving averages signaling sell pressure, though RSI levels suggest potential oversold conditions. The fund faces headwinds from UK economic concerns including rising gilt yields and inflation pressures, while recent government housing initiatives provide some sector-specific support.

The outlook remains cautious as UK economic vulnerabilities and rising borrowing costs weigh on sentiment. Investment opportunity exists for long-term investors seeking UK exposure at discounted levels, though near-term risks include persistent inflation and political uncertainty surrounding the upcoming budget announcement.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.

The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EWU

No sentiment data available yet.

ZBH
100% Buy0% Sell
Avg holding period · 89 Days

Top news

Latest headlines on both assets

About iShares MSCI United Kingdom (FTSE)

EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.

Read more on EWU →

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH →